MRNA VS. CONVENTIONAL VACCINES Meet our new Chief Patient Officer,
Read moreIn His Shoes (or Hiking Boots): William’s epic solo adventure to help fellow hemophilia patients in need
Home »
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE:
Read morePfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE) October 07, 2020 —
Read moreEmicizumab Prophylaxis Cuts Bleeding in Hemophilia A
WEDNESDAY, Aug. 29, 2018 — For patients with hemophilia A
Read more